Evidence map›Paper›PMID 26437728›Full record

ArticleAustralian and New Zealand journal of public health2015

Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy.

Susan J Jordan, Louise F Wilson, Christina M Nagle, Adele C Green, Catherine M Olsen, Christopher J Bain, Nirmala Pandeya, David C Whiteman, Penelope M Webb

Open access · hybridAbstract read
In one paragraph

Article in Australian and New Zealand journal of public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Susan J JordanQIMR Berghofer Medical Research Institute, Queensland.
Louise F WilsonQIMR Berghofer Medical Research Institute, Queensland.
Christina M NagleQIMR Berghofer Medical Research Institute, Queensland.
Adele C GreenQIMR Berghofer Medical Research Institute, Queensland.
Catherine M OlsenQIMR Berghofer Medical Research Institute, Queensland.
Christopher J BainQIMR Berghofer Medical Research Institute, Queensland.
Nirmala PandeyaQIMR Berghofer Medical Research Institute, Queensland.
David C WhitemanQIMR Berghofer Medical Research Institute, Queensland.
Penelope M WebbQIMR Berghofer Medical Research Institute, Queensland.
University of Queensland · AUQIMR Berghofer Medical Research Institute · AUAustralian National University · AUCancer Research UK Manchester Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo estimate the proportion and number of cancers occurring in Australia in 2010 attributable to menopausal hormone therapy (MHT) use.

methodsWe estimated the population attributable fraction for cancers causally associated with MHT (breast, endometrium, ovary), and the proportion of colorectal cancers prevented by MHT. We used standard formulae incorporating Australian prevalence data, relative risks of cancer associated with MHT and cancer incidence. We also estimated potential change in cancer incidence under two hypothetical scenarios whereby 25% fewer Australian women used MHT, or women exclusively used oestrogen-only MHT.

resultsAn estimated 539 cancers in Australia in 2010 were attributable to MHT: 453 breast, 67 endometrial and 19 ovarian cancers equating to 3.4%, 3.1% and 1.6% of each cancer type, respectively. In contrast, MHT may have prevented 52 colorectal cancers. If 25% fewer women used MHT, then 141 cancers may have been avoided. If women exclusively used oestrogen-only MHT then 240 cancers may have been avoided.

conclusionsMHT use caused more than 500 cancers in Australian women in 2010 and prevented ∼50 colorectal cancers. IMPLICATIONS: MHT use continues to cause an excess of cancers. The risks, benefits, regimen and treatment duration should be carefully considered for each woman before MHT is commenced.

Indexed as

MenopauseAdultAustraliaBreast NeoplasmsColorectal NeoplasmsEndometrial NeoplasmsEstrogen Replacement TherapyFemaleHumansIncidenceMiddle AgedOvarian NeoplasmsPrevalenceRisk AssessmentRisk Factorscancermenopausal hormone therapypopulation attributable fractionpotential impact fractionrisk factor

Identifiers

PMID26437728
PMCPMC4606777
OpenAlexW1897252907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.